Citi raised the firm’s price target on Arvinas (ARVN) to $24 from $21 and keeps a Buy rating on the shares after the company received FDA approval of Veppanu for ESR1m ER+ HER2- breast cancer patients who progressed on at least one line of endocrine therapy. Citi believes the approval “importantly de-risks” Arvinas’ degrader platform.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN: